Enzene, an India-based biopharmaceutical manufacturing company, released NeX on August 3, 2026. It is a partnership program that aid government authorities, institutions, and biopharma companies build advanced local facilities to produce biologic medicines.
NeX is based on Enzene’s EnzeneX continuous manufacturing technology, which helps produce medicines in a faster, more cost-effective, and sustainable way. The program provides support for facility setup, technology transfer, training, as well as ongoing operations. It aims to help regions improve access to biologic medicines, strengthen local manufacturing, develop skilled workers, and reduce production costs.
According to Coherent Market Insights, the Digital Biomanufacturing Market is projected to grow at a CAGR of 18.5% during 2026 to 2033. Currently, the market is at USD 2.8 Billion in 2026 and is expected to be around USD 8.7 Billion by 2033. Digital biomanufacturing involves the digital technologies to improve the manufacturing process. It helps to enhanced the biological manufacturing by using computer aided design, verification and manufacture. Digital biomanufacturing addresses unique aspects of biological activities and increase the data collection, monitoring, process control algorithms, automation, etc.
"Conventional biologics plant often requires between USD300 million and USD400 million to build," commented Himanshu Gadgil, Ph.D., CEO of Enzene. "With our fully-connected continuous manufacturing platform, the same output can be achieved for USD60–USD80 million. The efficiency comes from a compact, integrated system architecture rather than the scale-intensive layouts of fed-batch facilities, allowing for long-term cost advantage and high product yields for locally manufactured biomedicines. We are already engaged in discussions with multiple governments and corporations all around the world and are looking forward to helping deliver affordable medicines to patients worldwide."
Enzene is a biopharmaceutical development and manufacturing company that helps drug developers and biosimilar companies from research to commercial production. The company operates facilities in India and the U.S. and provides biologics manufacturing services using its EnzeneX® continuous manufacturing technology, which helps improve production efficiency and reduce costs.
Source:
News Release: Enzene
Company: Enzene
